<?xml version="1.0" encoding="UTF-8"?>
<p id="p0065">Because of the high sequence similarity of different CoV 3CLpros, a lot of previously described inhibitors can be considered to be of great use in the current SARS-CoV-2. A majority of inhibitors of the 3CLpro are covalent in nature, binding to the active-site cysteine (
 <xref rid="sch1" ref-type="fig">Scheme 1</xref> ). Different electrophilic warheads are known, including α-halocarbonyl, acrylamides, sulfonyl chlorides, aldehydes (
 <bold>2</bold>),
 <xref rid="bib9" ref-type="bibr">
  <sup>9</sup>
 </xref> isatines (
 <bold>3</bold>),
 <xref rid="bib10" ref-type="bibr">
  <sup>10</sup>
 </xref> or α-ketoheteraromates (
 <bold>4</bold>).
 <xref rid="bib6" ref-type="bibr">
  <sup>6</sup>
 </xref> Many of the molecules are rather large and are based on extensive amide chemistry, mimicking part of the peptide substrate of the protease. Moreover, their selectivity toward other potential targets in the human body has not been established.
</p>
